Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number Filing Date February 17, 2004 INFORMATION DISCLOSURE First Named Inventor Hector F. DeLuca STATEMENT BY APPLICANT Art Unit 1616 (Use as many sheets as necessary) **Examiner Name** Qazi, Sabiha Naim 1256-00947 Attorney Docket Number

Cite No. <sup>1</sup>		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
<del>  /</del>	Number-King Code	<del>-</del>		rigules Appeal
	<sup>03-</sup> 6,392,071	05-21-2002	DeLuca et al	_
		08-31-1999	DeLuca et al	
		08-10-1999	DeLuca et al	
	<sup>US-</sup> 5,877,168	03-02-1999	Miyamoto et al	
	<sup>US-</sup> 5,849,726	12-15-1988	Brenner	
	<sup>US-</sup> 5,846,960	12-08-1998	Labrie	
$\eta$	<sup>US-</sup> 5,843,928	12-01-1998	DeLuca et al	
, 1		12-01-1998	DeLuca	
		10-06-1998	Kutner et al	
	<sup>US-</sup> 5,587,497	12-24-1996	DeLuca et al	
	<sup>US-</sup> 5,536,713	07-16-1996	DeLuca et al	
	<sup>US-</sup> 5,246,925	09-21-1993	DeLuca et al	
		08-17-1993	DeLuca et al	
		02-04-1992	DeLuca et al	
	US- 4,666,634	05-19-1987	Miyamoto et al	
	US-			
	Cite No.1	Number-Kind Code <sup>2 (# known)</sup> US- 6,392,071 US- 5,945,410 US- 5,936,133 US- 5,877,168 US- 5,849,726 US- 5,846,960 US- 5,843,928 US- 5,843,927 US- 5,843,927 US- 5,847,648 US- 5,587,497 US- 5,536,713 US- 5,246,925 US- 5,237,110 US- 5,086,191 US- 4,666,634 US- US- US- US-	Cite No.¹         Document Number         Publication Date MM-DD-YYYY           US- 6,392,071         05-21-2002           US- 5,945,410         08-31-1999           US- 5,936,133         08-10-1999           US- 5,877,168         03-02-1999           US- 5,849,726         12-15-1988           US- 5,846,960         12-08-1998           US- 5,843,928         12-01-1998           US- 5,843,927         12-01-1998           US- 5,817,648         10-06-1998           US- 5,587,497         12-24-1996           US- 5,246,925         09-21-1993           US- 5,237,110         08-17-1993           US- 5,086,191         02-04-1992           US- 4,666,634         05-19-1987           US- US-         US-	Number-Kind Code <sup>2 (# known)</sup>

		FORE	IGN PATENT DOCL	IMENTS		-
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T <sup>6</sup>
	6	0184206	12-04-1985	Europe		<b>T</b>
sh		0078704	04-29-1987	Europe		
A. Y'	1 7	0387077	09-03-1990	Europe		
5		0474517	11-03-1992	Europe		
		0480572	04-15-1992	Europe		
		0516410	12-02-1992	Europe		

Examiner Date Signature Considered

\*EXAMINER: Initial if reference considered, whether or not/citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** Filing Date February 17, 2004 INFORMATION DISCLOSURE First Named Inventor Hector F. DeLuca STATEMENT BY APPLICANT Art Unit 1616 (Use as many sheets as necessary) Qazi, Sabiha Naim **Examiner Name Attorney Docket Number** 1256-00947

			U. S. PATENT I	DOCUMENTS	
Examiner Initials*	Cite No.	Document Number  Number-Kind Code <sup>2 (# known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		NS-			
		US-	<u> </u>		
		US-			
		US-			
	<u> </u>	US-	ļ	·	<del>  \                                   </del>
		US-	<del> </del>		
		US-	<del>\</del>	<u> </u>	<del>                                     </del>
		US-			
	<u> </u>	US-	+		<del>                                     </del>
	<del> </del>	US-			
	<del></del>	US-	<del>                                     </del>	<del>\                                    </del>	
	├	US-	<del> </del>	<del></del>	
<del></del>		US-			
		US-	1		
	<u> </u>	US-			
	<del></del>	US-			

			GN PATENT DOCL	JMENTS		
Examiner Cite	Cite No.1	Foreign Patent Document	Foreign Patent Document Publication Date		Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (# known)	MM-DD-YYYY		Or Relevant Figures Appear	
OF	2-4	WO90/09991	09-07-1990	Calverley et al		
50		WO96/01811	01-25-1996	Posner		Γ
	<u> </u>					L
	<u> </u>					Ļ
			<u> </u>			L
						Γ

Examiner Date Signature Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not/in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. \*Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or relain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	for form 1449/PTO			e required to respond to a collection	Complete if Known		
				Application Number			
INFO	RMATIO	V DIS	CLOSURE	Filing Date	February 17, 2004		
STAT	EMENT	BY A	PPLICANT	First Named Inventor	Hector F. DeLuca		
	(Use as many sh	noote ae ni	ocaceand	Art Unit	1616		
(coo to many should as housessary)				Examiner Name	Qazi, Sabiha Naim		
Sheet	3	of	4	Attorney Docket Number	1256-00947		

Examiner	Cite	Include name of the outbox (in CARITAL LETTERS) site of the site of the	
Initials*	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Baggiolini et al, "Stereochemical Total Synthesis of 1a,25-Dihydroxycholecalciferol and 1Beta,25-Dihydroxyerocalciferol", Journal of Organic Chemistry, 51, pp. 3098-3108, 1986.	
<u>-</u>		Bouillon et al, "Biological Activity of Dihydroxylated 19-Nor-(Pre)Vitamin D3", Bioactivity of 19-Nor-Pre D, Vol. 8, No. 8, pp. 1009-1015, 1993.	
		Chemical Abstracts, "Chemistry of Synthetic High Polymers", Vol. 110, No. 10, Abstract 110: 82505v, March 6, 1989.	
		Chemical Abstracts, XP-002066055, Vol. 121, No. 21, November 21, 1994.	
	2	Fujishima et al, "Synthesis and Biological Activity of 2-Methyl-20-EPI Analogues of 1Alpha,25-Dihydroxyvitamin D3," Bioorganic & Medicinal Chemistry Letters, 8, pp. 2145-2148, 1998.	
5		Kiegiel et al, "Chemical Conversion of Vitamin D3 to its 1,25-Dihydroxy Metabolite", Tetrahedron Letters, Vol. 31, No. 43, pp. 6057-60660, 1991.	
		Konno et al, "A Novel and Practical Route to A-Ring Enyne Synthon for 1Alpha,25-Dihydroxyvitamin D3 Analogs: Synthesis of A-ring Diastereomers of 1Alpha,25-Dihydroxy-Vitamin D3 and 2-Methyl-1,25-Dihydroxyvitamin D3," Bioorganic & Medicinal Chemistry Letters, 8, pp. 151-156, 1998.	
		Okano et al, "Regulatory Activities of 2b-(3-Hydroxypropoxy)-1a,25-Dihydroxyvitamin D3. A Novel Synthetic Vitamin D3 Derivative on Calcium Metabolism", Biochemical and Biophysical Research Communications, Vol. 163, No. 3, pp. 1444-1449, September 29, 1989.	
		Perlman et al, "1a,25-Dihydroxy-19-Nor-Vitamin D3. A Novel Vitamin D-Related Compound with Potential Therapeutic Activity", Tetrahedron Letters, Vol. 31, No. 13, pp. 1823-1824, February 1990.	
		Posner et al, "2-Fluoroalkyl A-Ring Analogs of 1,25-Dihydroxyvitamin D3-Stereocontrolled Total Synthesis via Intramolecular and Intermolecular Diels-Alder Cycloadditions. Preliminary Biological Testing", Journal of Organic Chemistry, 60, pp. 4617-4628, 1995.	

Examiner	100		Date	1	
Signature	Sabiha	Qana	Considered	9/26/04	

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
of a collection of information unless it contains a valid OMB control purpose. Under the Panerwork Reduction Act of 1995, no persons are required to

Substitut	te for form 1449/PTC	 )			Complete if Known	
				Application Number		
INFO	DRMATIO	N DIS	CLOSURE	Filing Date	February 17, 2004	
STA	TEMENT	BY A	PPLICANT	First Named Inventor	Hector F. DeLuca	
	(Use as many s	hoots as no	cessen)	Art Unit	1616	
(000 00 110000 00 1100000017)				Examiner Name	Qazi, Sabiha Naim	
Sheet	4	of	4	Attorney Docket Number	1256-00947	

Cunning:	C:4-	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Posner et al, "Stereocontrolled Synthesis of a Trihydroxylated A Ring as an Immediate Precursor to 1Alpha,2Alpha,25-Trihydroxyvitamin D3", Journal of Organic Chemistry, 56, pp. 4339-4341, April 15, 1995.	
		Sarandeses et al, "Synthesis of 1Alpha,25-Dihydroxy-19-Norprevitamin D3", tetrahedron Letters, pp. 5445-5448, April 1992.	
509	2	Sicinski et al, "New 1Alpha,25-Dihydroxy-19-Norvitamin D3 Compounds of High Biological Activity: Synthesis and Biological Evaluation of 2-Hydroxymethyl, 2-Methyl, and 2-Methylene Analogues," Journal of Medical Chemistry, 41, pp. 4662-4674, 1998.	
		Slatopolsky et al, "A New Analog of Calcitriol, 19-Nor-1,25-(OH)2 D2 Suppresses Parathyroid Hormone Secretion in Uremic Rats in the Absence of Hypercalcemia", American Journal of Kidney Disorders, 26(5), 832-60, 1995.	
	-	Suhara et al, "Synthesis and Biological Evaluation of Novel 2Alpha-Substituted 1Alpha,25-Dihydroxyvitamin D3 Analogues," Biolorganic & Medicinal Chemistry Letters, 10, pp. 1129-1132, March 16, 2000.	
,	. /		

Examiner Signature	Sakiha	Qazz	Date Considered	9/26/04	
*FYAMINED. I	itial if rafarance appointment b . th	A - 14 - 15 1 - 1 / A		<del></del>	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.